Home » Topics » Regulatory

Regulatory
RSS

Mylan antianxiety/antipsychotic generic approved by FDA

July 14, 1997

Profile of a new formulation of eperisone hydrochloride

July 14, 1997

Knoll receives FDA approval to market Mavik for new indication

July 14, 1997

Ergo Science's Ergoset enters phase II/III trials in obesity

July 14, 1997

Mylan, Purepac and ESI Lederle report FDA generic approvals

July 14, 1997

Once-daily extended-release venlafaxine evaluated in depression

July 11, 1997

Generic etodolac approved by FDA

July 11, 1997

Sparta's Spartaject busulfan enters phase I

July 11, 1997

Smoking cessation treatment launched in the U.S.

July 10, 1997

New clinical uses of risperidone investigated

July 10, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Nov. 8, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for November 8, 2024.
Sales balloon for GLP-1 drugs from Novo Nordisk, Eli Lilly
BioWorld
Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide-1 (GLP-1) drugs to treat obesity....
Regulatory actions for Oct. 31, 2024
BioWorld
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Capsida, Electra,...
Australia reimburses Vazkepa a decade after US approval
BioWorld
For the first time, Australians have access to CSL Inc.’s Vazkepa (icosapent ethyl/Vascepa) for managing cardiovascular disease more than a decade after the drug...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.